Biocept has initiated the full commercial launch of CNSide, its cerebrospinal fluid (CSF) assay that helps identify and manage the treatment of metastatic cancers involving the central nervous system (CNS).
First introduced in January last year, CNSide is based on Biocept’s proprietary quantitative tumour cell capture and detection method coupled with tests to detect actionable molecular treatment targets.
It provides a timely and precise approach to diagnose disease, detect actionable biomarkers and evaluate therapy response, which could have an effect on life expectancy and quality of life for patients.
